Abstract Body

This presentation will focus on three controversies in hepatitis B treatment in people living with and without HIV infection. Controversies discussed include discontinuing nucleoside analogue therapy, screening for HCC with long-term suppression of HBV DNA on nucelos(t)ide analogue therapy, and treatment of immunotolerant chronic hepatitis B. The most recent data on these controversies will be reviewed.